Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

Thomas WiegelPeter AlbersDetlef BartkowiakRoswitha Bussar-MaatzMartin HärterGlen KristiansenPeter MartusStefan WellekHeinz SchmidbergerKlaus GrozingerPeter RennerFried SchneiderMartin BurmesterMichael Stöckle

Published in: Journal of cancer research and clinical oncology (2020)

In this prematurely closed trial, we observed an unexpected high rate of termination of AS and an increased toxicity related to PSI. Patients hesitated to be randomized in a multi-arm trial. The optimal treatment of low and early-intermediate risk PCa remains unclear.

Keyphrases

phase iii
prostate cancer
phase ii
study protocol
clinical trial
open label
end stage renal disease
chronic kidney disease
double blind
oxidative stress
prognostic factors
smoking cessation